BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral interferon-alpha lozenges: Preliminary Phase II data

Preliminary data from a double-blind, placebo-controlled, Australian Phase II trial in 200 healthy volunteers vaccinated with the Fluvax influenza vaccine prior to the study showed that once-daily oral interferon-alpha lozenges for 16 weeks significantly reduced the incidence of influenza-like illness by 28% (p=0.01). Oral interferon-alpha lozenges also significantly...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >